Neurogene (NGNE) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

—

Estimate

-$1.37

Surprise

—

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

• Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166 — benzinga, 2026-08-12
• Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81 — benzinga, 2026-08-12
• HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65 — benzinga, 2026-08-12

TrendMatrix currently rates NGNE Sell at 5.5/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$38.63

Price target

$69.97

Stop

$35.93

Upside to target

+81.1%

Reward-to-risk

5.4:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$773.0M

P/E (fwd)

-7.5

52-week range

$15.93–$43.66

Off 52-week high

11.5%

RSI (14)

69

Volume vs avg

1.91×

Score today

5.5/10